Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.